<td class= (Institución)
   (Nuevo usuario)
Ayuda  | Contacto  |  Castellano English  

Dadun > Depósito Académico > Clínica Universidad de Navarra > Pediatría > DA - CUN - Pediatría - Artículos de revista >

Methotrexate in Pediatric Osteosarcoma: Response and Toxicity in Relation to Genetic Polymorphisms and Dihydrofolate Reductase and Reduced Folate Carrier 1 Expression
Autor(es) : Patiño, A. (Ana)
Zalacain, M. (Marta)
Marrodan, L. (Lucía)
San-Julian, M. (Mikel)
Sierrasesumaga, L. (Luis)
Palabras clave : Methotrexate/administration & dosage/adverse effects
Polymerase Chain Reaction
Osteosarcoma/drug therapy/genetics/mortality
Fecha incorporación: 2009
Editorial : Elsevier
Versión del editor: http://dx.doi.org/10.1016/j.jpeds.2008.11.030
ISSN: 0022-3476
Cita: Patiño-García A, Zalacaín M, Marrodán L, San-Julián M, Sierrasesúmaga L. Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression. J Pediatr. 2009 May;154(5):688-93.
To determine the influence of the genotype and the level of expression of different enzymes involved in folate metabolism on the response to and toxicity of high-dose methotrexate treatment in pediatric osteosarcomas. STUDY DESIGN: DHFR and Reduced folate carrier 1 (RFC1) semiquantitative expression was analyzed in 34 primary and metastatic osteosarcoma tissues by real-time polymerase chain reaction. The following polymorphisms were also analyzed in peripheral blood from 96 children with osteosarcoma and 110 control subjects: C677T, A1298C (MTHFR), G80A (RFC1), A2756G (MTR), C1420T (SHMT), the 28bp-repeat polymorphism, and 1494del6 of the TYMS gene. Treatment toxicity was scored after each cycle according to criteria from the World Health Organization. RESULTS: DHFR and RFC1 expression was lower in initial osteosarcoma biopsy specimens than in metastases (P = .024 and P = .041, respectively). RFC1 expression was moderately decreased in samples with poor histologic response to preoperative treatment (P = .053). Patients with osteosarcoma with G3/G4 hematologic toxicity were more frequently TT than CT/CC for C677T/MTHFR (P = .023) and GG for A2756G/MTR (P = .048 and P = .057 for gastrointestinal and hematologic toxicity, respectively). CONCLUSIONS: The role of C677T/MTHFR and A2756G/MTR on chemotherapy-induced toxicity should be further investigated in pediatric osteosarcomas receiving high-dose methotrexate. Altered expression of DHFR and RFC1 is a feasible mechanism by which osteosarcoma cells become resistant to methotrexate.
Enlace permanente: http://hdl.handle.net/10171/23770
Aparece en las colecciones: DA - CUN - Cirugía ortopédica y traumatología - Artículos de revista
DA - CUN - Pediatría - Artículos de revista

Ficheros en este registro:
Fichero:  J Pediatr.2009.688.pdf
Tamaño:  175,19 kB
Formato:  Adobe PDF
 Visualizar / Abrir 

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.